Samvel B. Gasparyan

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Response by Myte et al to Letter Regarding Article, "Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin".

Response by Myte et al to Letter Regarding Article, "Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin".

Journal: Circulation. Heart failure

Published: April 15, 2026

Characterizing Treatment Effects on Patient-Reported Outcomes in Heart Failure Trials.

Characterizing Treatment Effects on Patient-Reported Outcomes in Heart Failure Trials.

Journal: Circulation. Population health and outcomes

Published: February 16, 2026

A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis.

A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: November 24, 2025

Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.

Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.

Journal: Circulation. Heart failure

Published: October 31, 2025

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.

Journal: Lancet (London, England)

Published: August 29, 2025

The authors reply.

The authors reply.

Journal: Kidney international

Published: June 03, 2025

The Univariate Distribution of Hierarchical Composite Endpoints and the Condorcet Non-transitivity Paradox.

The Univariate Distribution of Hierarchical Composite Endpoints and the Condorcet Non-transitivity Paradox.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: May 27, 2025

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.

Journal: Cardiovascular diabetology

Published: April 28, 2025

Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.

Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.

Journal: Journal of the American Society of Nephrology : JASN

Published: December 20, 2024

Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint.

Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint.

Journal: Kidney international

Published: November 27, 2024

Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.

Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.

Journal: European journal of heart failure

Published: April 19, 2024

Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.

Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.

Journal: Journal of the American College of Cardiology

Published: March 13, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026